There are a large number of publications which describe the use of cyclodextrins (CDs) in numerous fields, including biomedicine, cosmetics, food industry, wastewater remediation and catalysis.1 These drugs contain a number of glucose monomers in a ring, creating a cone shape: α (alpha), β (beta), and γ (gamma) cyclodextrins with 6, 7 and 8 glucose subunits respectively. With a hydrophobic interior and hydrophilic exterior, they can form complexes with hydrophobic compounds often conferring solubility and stability to other drugs. The inclusion compounds of cyclodextrins with hydrophobic molecules are able to penetrate body tissues; these can be used to release biologically active compounds under specific conditions.2
Sugammadex is a unique, selective relaxant binding agent (SRBA) which reverses aminosteroid-induced neuromuscular blockade. It is an alternative to anticholinesterases in anaesthesia and allows use and reversal of rocuronium as a substitute for suxamethonium for rapid sequence induction (RSI).3,4
By submitting manuscripts to SAJAA, authors of original articles are assigning copyright to the SA Society of Anaesthesiologists. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAJAA for educational and research purposes without obtaining permission.
The work is licensed under a Creative Commons Attribution-Non-Commercial Works 4.0 South Africa License. The SAJAA does not hold itself responsible for statements made by the authors.